Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)
China
· Delayed Price · Currency is CNY 26.45
+0.30 (1.15%)
Apr 29, 2026, 2:14 PM CST
SHA:600645 Revenue
Vcanbio Cell & Gene Engineering Corp., had revenue of 317.34M CNY in the quarter ending March 31, 2026, a decrease of -9.54%. This brings the company's revenue in the last twelve months to 1.42B, down -7.59% year-over-year. In the year 2025, Vcanbio Cell & Gene Engineering Corp., had annual revenue of 1.45B, down -8.23%.
Revenue (ttm)
1.42B
Revenue Growth
-7.59%
P/S Ratio
8.39
Revenue / Employee
705.81K
Employees
2,014
Market Cap
11.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.45B | -130.47M | -8.23% |
| Dec 31, 2024 | 1.59B | -4.30M | -0.27% |
| Dec 31, 2023 | 1.59B | 34.84M | 2.24% |
| Dec 31, 2022 | 1.55B | 19.56M | 1.27% |
| Dec 31, 2021 | 1.54B | 216.43M | 16.41% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| InventisBio | 37.29M |
| Tibet Cheezheng Tibetan Medicine | 2.42B |
| Chengdu Olymvax Biopharmaceuticals | 704.16M |
| Chongqing Genrix Biopharmaceutical | 230.72M |
| Staidson (Beijing) BioPharmaceuticals | 244.37M |
| Hualan Biological Vaccine | 1.20B |
| Chengdu Easton Biopharmaceuticals | 1.35B |